Thus, HER2 was elevated in 7 of 8 premenopausal tumours (individual ratio: 2.64; CI: 1.50-4.63, P=0.017) and HER3 in 8 of 8 individuals (individual ratio: 16.96; CI: 4.02-71.52, P=0.012). This evidence concerns the gene ERBB3 and neoplasm.